NCT00939731View on ClinicalTrials.gov

Relative Drug Exposures Of Two Formulations of PF-02341066

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Healthy
Interventions
DRUG

PF-02341066

A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Powder-in-Capsule and 2 x 100-mg Powder-in-Capsules

DRUG

PF-02341066

A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Immediate Release Tablet and 2 x 100-mg Immediate Release Tablets

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00939731 - Relative Drug Exposures Of Two Formulations of PF-02341066 | Biotech Hunter | Biotech Hunter